1
|
Budusan E, Payne CD, Gonzalez TI, Obergrussberger A, Becker N, Clark RJ, Johan Rosengren K, Rash LD, Cristofori-Armstrong B. The funnel-web spider venom derived single knot peptide Hc3a modulates acid-sensing ion channel 1a desensitisation. Biochem Pharmacol 2024:116175. [PMID: 38552850 DOI: 10.1016/j.bcp.2024.116175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2024] [Revised: 03/17/2024] [Accepted: 03/26/2024] [Indexed: 04/07/2024]
Abstract
Acid-sensing ion channel 1a (ASIC1a) is a proton-gated channel involved in synaptic transmission, pain signalling, and several ischemia-associated pathological conditions. The spider venom-derived peptides PcTx1 and Hi1a are two of the most potent ASIC1a inhibitors known and have been instrumental in furthering our understanding of the structure, function, and biological roles of ASICs. To date, homologous spider peptides with different pharmacological profiles at ASIC1a have yet to be discovered. Here we report the characterisation of Hc3a, a single inhibitor cystine knot peptide from the Australian funnel-web spider Hadronyche cerberea with sequence similarity to PcTx1. We show that Hc3a has complex pharmacology and binds different ASIC1a conformational states (closed, open, and desensitised) with different affinities, with the most prominent effect on desensitisation. Hc3a slows the desensitisation kinetics of proton-activated ASIC1a currents across multiple application pHs, and when bound directly to ASIC1a in the desensitised conformation promotes current inhibition. The solution structure of Hc3a was solved, and the peptide-channel interaction examined via mutagenesis studies to highlight how small differences in sequence between Hc3a and PcTx1 can lead to peptides with distinct pharmacology. The discovery of Hc3a expands the pharmacological diversity of spider venom peptides targeting ASIC1a and adds to the toolbox of compounds to study the intricacies of ASIC1 gating.
Collapse
Affiliation(s)
- Elena Budusan
- School of Biomedical Sciences, The University of Queensland, St Lucia, QLD, Australia
| | - Colton D Payne
- School of Biomedical Sciences, The University of Queensland, St Lucia, QLD, Australia
| | - Tye I Gonzalez
- School of Biomedical Sciences, The University of Queensland, St Lucia, QLD, Australia
| | | | | | - Richard J Clark
- School of Biomedical Sciences, The University of Queensland, St Lucia, QLD, Australia
| | - K Johan Rosengren
- School of Biomedical Sciences, The University of Queensland, St Lucia, QLD, Australia.
| | - Lachlan D Rash
- School of Biomedical Sciences, The University of Queensland, St Lucia, QLD, Australia.
| | - Ben Cristofori-Armstrong
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia.
| |
Collapse
|
2
|
Petkova-Kirova P, Murciano N, Iacono G, Jansen J, Simionato G, Qiao M, Van der Zwaan C, Rotordam MG, John T, Hertz L, Hoogendijk AJ, Becker N, Wagner C, Von Lindern M, Egee S, Van den Akker E, Kaestner L. The Gárdos Channel and Piezo1 Revisited: Comparison between Reticulocytes and Mature Red Blood Cells. Int J Mol Sci 2024; 25:1416. [PMID: 38338693 PMCID: PMC10855361 DOI: 10.3390/ijms25031416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 12/28/2023] [Accepted: 01/03/2024] [Indexed: 02/12/2024] Open
Abstract
The Gárdos channel (KCNN4) and Piezo1 are the best-known ion channels in the red blood cell (RBC) membrane. Nevertheless, the quantitative electrophysiological behavior of RBCs and its heterogeneity are still not completely understood. Here, we use state-of-the-art biochemical methods to probe for the abundance of the channels in RBCs. Furthermore, we utilize automated patch clamp, based on planar chips, to compare the activity of the two channels in reticulocytes and mature RBCs. In addition to this characterization, we performed membrane potential measurements to demonstrate the effect of channel activity and interplay on the RBC properties. Both the Gárdos channel and Piezo1, albeit their average copy number of activatable channels per cell is in the single-digit range, can be detected through transcriptome analysis of reticulocytes. Proteomics analysis of reticulocytes and mature RBCs could only detect Piezo1 but not the Gárdos channel. Furthermore, they can be reliably measured in the whole-cell configuration of the patch clamp method. While for the Gárdos channel, the activity in terms of ion currents is higher in reticulocytes compared to mature RBCs, for Piezo1, the tendency is the opposite. While the interplay between Piezo1 and Gárdos channel cannot be followed using the patch clamp measurements, it could be proved based on membrane potential measurements in populations of intact RBCs. We discuss the Gárdos channel and Piezo1 abundance, interdependencies and interactions in the context of their proposed physiological and pathophysiological functions, which are the passing of small constrictions, e.g., in the spleen, and their active participation in blood clot formation and thrombosis.
Collapse
Affiliation(s)
- Polina Petkova-Kirova
- Institute of Neurobiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria;
- Department of Biochemistry, Saarland University, 66123 Saarbrücken, Germany
| | - Nicoletta Murciano
- Nanion Technologies, 80339 Munich, Germany; (N.M.); (M.G.R.); (N.B.)
- Theoretical Medicine and Biosciences, Campus University Hospital, Saarland University, 66421 Homburg, Germany; (J.J.); (M.Q.); (L.H.)
| | - Giulia Iacono
- Department of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; (G.I.); (C.V.d.Z.); (A.J.H.); (M.V.L.); (E.V.d.A.)
- Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1007 MB Amsterdam, The Netherlands
| | - Julia Jansen
- Theoretical Medicine and Biosciences, Campus University Hospital, Saarland University, 66421 Homburg, Germany; (J.J.); (M.Q.); (L.H.)
- Department of Experimental Physics, Saarland University, 66123 Saarbrücken, Germany (T.J.); (C.W.)
| | - Greta Simionato
- Department of Experimental Physics, Saarland University, 66123 Saarbrücken, Germany (T.J.); (C.W.)
- Department of Experimental Surgery, Campus University Hospital, Saarland University, 66421 Homburg, Germany
| | - Min Qiao
- Theoretical Medicine and Biosciences, Campus University Hospital, Saarland University, 66421 Homburg, Germany; (J.J.); (M.Q.); (L.H.)
- Department of Experimental Physics, Saarland University, 66123 Saarbrücken, Germany (T.J.); (C.W.)
| | - Carmen Van der Zwaan
- Department of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; (G.I.); (C.V.d.Z.); (A.J.H.); (M.V.L.); (E.V.d.A.)
- Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1007 MB Amsterdam, The Netherlands
| | | | - Thomas John
- Department of Experimental Physics, Saarland University, 66123 Saarbrücken, Germany (T.J.); (C.W.)
| | - Laura Hertz
- Theoretical Medicine and Biosciences, Campus University Hospital, Saarland University, 66421 Homburg, Germany; (J.J.); (M.Q.); (L.H.)
- Department of Experimental Physics, Saarland University, 66123 Saarbrücken, Germany (T.J.); (C.W.)
| | - Arjan J. Hoogendijk
- Department of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; (G.I.); (C.V.d.Z.); (A.J.H.); (M.V.L.); (E.V.d.A.)
- Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1007 MB Amsterdam, The Netherlands
| | - Nadine Becker
- Nanion Technologies, 80339 Munich, Germany; (N.M.); (M.G.R.); (N.B.)
| | - Christian Wagner
- Department of Experimental Physics, Saarland University, 66123 Saarbrücken, Germany (T.J.); (C.W.)
- Physics and Materials Science Research Unit, University of Luxembourg, L-1511 Luxembourg, Luxembourg
| | - Marieke Von Lindern
- Department of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; (G.I.); (C.V.d.Z.); (A.J.H.); (M.V.L.); (E.V.d.A.)
- Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1007 MB Amsterdam, The Netherlands
| | - Stephane Egee
- Biological Station Roscoff, Sorbonne University, CNRS, UMR8227 LBI2M, F-29680 Roscoff, France;
- Laboratory of Excellence GR-Ex, F-75015 Paris, France
| | - Emile Van den Akker
- Department of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; (G.I.); (C.V.d.Z.); (A.J.H.); (M.V.L.); (E.V.d.A.)
- Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1007 MB Amsterdam, The Netherlands
| | - Lars Kaestner
- Theoretical Medicine and Biosciences, Campus University Hospital, Saarland University, 66421 Homburg, Germany; (J.J.); (M.Q.); (L.H.)
- Department of Experimental Physics, Saarland University, 66123 Saarbrücken, Germany (T.J.); (C.W.)
| |
Collapse
|
3
|
Murciano N, Rotordam MG, Becker N, Ludlow MJ, Parsonage G, Darras A, Kaestner L, Beech DJ, George M, Fertig N, Rapedius M, Brüggemann A. A high-throughput electrophysiology assay to study the response of PIEZO1 to mechanical stimulation. J Gen Physiol 2023; 155:e202213132. [PMID: 37801066 PMCID: PMC10558326 DOI: 10.1085/jgp.202213132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Revised: 07/17/2023] [Accepted: 09/17/2023] [Indexed: 10/07/2023] Open
Abstract
PIEZO1 channels are mechanically activated cation channels that play a pivotal role in sensing mechanical forces in various cell types. Their dysfunction has been associated with numerous pathophysiological states, including generalized lymphatic dysplasia, varicose vein disease, and hereditary xerocytosis. Given their physiological relevance, investigating PIEZO1 is crucial for the pharmaceutical industry, which requires scalable techniques to allow for drug discovery. In this regard, several studies have used high-throughput automated patch clamp (APC) combined with Yoda1, a specific gating modifier of PIEZO1 channels, to explore the function and properties of PIEZO1 in heterologous expression systems, as well as in primary cells. However, a combination of solely mechanical stimulation (M-Stim) and high-throughput APC has not yet been available for the study of PIEZO1 channels. Here, we show that optimization of pipetting parameters of the SyncroPatch 384 coupled with multihole NPC-384 chips enables M-Stim of PIEZO1 channels in high-throughput electrophysiology. We used this approach to explore differences between the response of mouse and human PIEZO1 channels to mechanical and/or chemical stimuli. Our results suggest that applying solutions on top of the cells at elevated pipetting flows is crucial for activating PIEZO1 channels by M-Stim on the SyncroPatch 384. The possibility of comparing and combining mechanical and chemical stimulation in a high-throughput patch clamp assay facilitates investigations on PIEZO1 channels and thereby provides an important experimental tool for drug development.
Collapse
Affiliation(s)
- Nicoletta Murciano
- Nanion Technologies GmbH, München, Germany
- Theoretical Medicine and Biosciences, Saarland University, Homburg, Germany
| | | | | | - Melanie J. Ludlow
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, UK
| | - Gregory Parsonage
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, UK
| | - Alexis Darras
- Experimental Physics, Saarland University, Saarbrücken, Germany
| | - Lars Kaestner
- Theoretical Medicine and Biosciences, Saarland University, Homburg, Germany
- Experimental Physics, Saarland University, Saarbrücken, Germany
| | - David J. Beech
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, UK
| | | | | | | | | |
Collapse
|
4
|
Hatem A, Esperti S, Murciano N, Qiao M, Giustina Rotordam M, Becker N, Nader E, Maurer F, Pérès L, Bouyer G, Kaestner L, Connes P, Egée S. Adverse effects of delta-9-tetrahydrocannabinol on sickle red blood cells. Am J Hematol 2023; 98:E383-E386. [PMID: 37800361 DOI: 10.1002/ajh.27109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 08/31/2023] [Accepted: 09/09/2023] [Indexed: 10/07/2023]
Abstract
THC triggers a pronounced entry of Ca2+ , which may be deleterious, into sickle cell red blood cells via activation of the TRPV2 channel.
Collapse
Affiliation(s)
- Aline Hatem
- Sorbonne Université, CNRS, UMR8227 LBI2M, Station Biologique de Roscoff, Roscoff, France
- Laboratory of Excellence GR-Ex, Paris, France
| | - Sofia Esperti
- Laboratory LIBM EA7424, Vascular Biology and Red Blood Cell Team, University of Lyon, Lyon, France
| | - Nicoletta Murciano
- Research and Development, Nanion Technologies, Munich, Germany
- Theoretical Medicine and Biosciences, Saarland University, Homburg, Germany
| | - Min Qiao
- Theoretical Medicine and Biosciences, Saarland University, Homburg, Germany
- Experimental Physics, Saarland University, Saarbrücken, Germany
| | | | - Nadine Becker
- Research and Development, Nanion Technologies, Munich, Germany
| | - Elie Nader
- Laboratory LIBM EA7424, Vascular Biology and Red Blood Cell Team, University of Lyon, Lyon, France
| | - Felix Maurer
- Experimental Physics, Saarland University, Saarbrücken, Germany
| | - Laurent Pérès
- Sorbonne Université, CNRS, UMR8227 LBI2M, Station Biologique de Roscoff, Roscoff, France
- Laboratory of Excellence GR-Ex, Paris, France
| | - Guillaume Bouyer
- Sorbonne Université, CNRS, UMR8227 LBI2M, Station Biologique de Roscoff, Roscoff, France
- Laboratory of Excellence GR-Ex, Paris, France
| | - Lars Kaestner
- Theoretical Medicine and Biosciences, Saarland University, Homburg, Germany
- Experimental Physics, Saarland University, Saarbrücken, Germany
| | - Philippe Connes
- Laboratory LIBM EA7424, Vascular Biology and Red Blood Cell Team, University of Lyon, Lyon, France
| | - Stéphane Egée
- Sorbonne Université, CNRS, UMR8227 LBI2M, Station Biologique de Roscoff, Roscoff, France
- Laboratory of Excellence GR-Ex, Paris, France
| |
Collapse
|
5
|
Parsonage G, Cuthbertson K, Endesh N, Murciano N, Hyman AJ, Revill CH, Povstyan OV, Chuntharpursat‐Bon E, Debant M, Ludlow MJ, Futers TS, Lichtenstein L, Kinsella JA, Bartoli F, Rotordam MG, Becker N, Brüggemann A, Foster R, Beech DJ. Improved PIEZO1 agonism through 4-benzoic acid modification of Yoda1. Br J Pharmacol 2023; 180:2039-2063. [PMID: 36457143 PMCID: PMC10952572 DOI: 10.1111/bph.15996] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 10/03/2022] [Accepted: 11/06/2022] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND AND PURPOSE The protein PIEZO1 forms mechanically activated, calcium-permeable, non-selective cation channels in numerous cell types from several species. Options for pharmacological modulation are limited and so we modified a small-molecule agonist at PIEZO1 channels (Yoda1) to increase the ability to modulate these channels. EXPERIMENTAL APPROACH Medicinal chemistry generated Yoda1 analogues that were tested in intracellular calcium and patch-clamp assays on cultured cells exogenously expressing human or mouse PIEZO1 or mouse PIEZO2. Physicochemical assays and wire myography assays on veins from mice with genetic disruption of PIEZO1. KEY RESULTS A Yoda1 analogue (KC159) containing 4-benzoic acid instead of the pyrazine of Yoda1 and its potassium salt (KC289) have equivalent or improved reliability, efficacy and potency, compared with Yoda1 in functional assays. Tested against overexpressed mouse PIEZO1 in calcium assays, the order of potency (as EC50 values, nM) was KC289, 150 > KC159 280 > Yoda1, 600). These compounds were selective for PIEZO1 over other membrane proteins, and the physicochemical properties were more suited to physiological conditions than those of Yoda1. The vasorelaxant effects were consistent with PIEZO1 agonism. In contrast, substitution with 2-benzoic acid failed to generate a modulator. CONCLUSION AND IMPLICATIONS 4-Benzoic acid modification of Yoda1 improves PIEZO1 agonist activity at PIEZO1 channels. We suggest naming this new modulator Yoda2. It should be a useful tool compound in physiological assays and facilitate efforts to identify a binding site. Such compounds may have therapeutic potential, for example, in diseases linked genetically to PIEZO1 such as lymphatic dysplasia.
Collapse
Affiliation(s)
- Gregory Parsonage
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of MedicineUniversity of LeedsLeedsUK
| | | | - Naima Endesh
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of MedicineUniversity of LeedsLeedsUK
| | - Nicoletta Murciano
- Nanion Technologies GmbHMunichGermany
- Theoretical Medicine and BiosciencesSaarland UniversityHomburgGermany
| | - Adam J. Hyman
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of MedicineUniversity of LeedsLeedsUK
| | | | - Oleksandr V. Povstyan
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of MedicineUniversity of LeedsLeedsUK
| | | | - Marjolaine Debant
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of MedicineUniversity of LeedsLeedsUK
| | - Melanie J. Ludlow
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of MedicineUniversity of LeedsLeedsUK
| | - Timothy Simon Futers
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of MedicineUniversity of LeedsLeedsUK
| | - Laeticia Lichtenstein
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of MedicineUniversity of LeedsLeedsUK
| | - Jacob A. Kinsella
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of MedicineUniversity of LeedsLeedsUK
| | - Fiona Bartoli
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of MedicineUniversity of LeedsLeedsUK
| | - Maria Giustina Rotordam
- Nanion Technologies GmbHMunichGermany
- Theoretical Medicine and BiosciencesSaarland UniversityHomburgGermany
| | | | | | | | - David J. Beech
- Leeds Institute of Cardiovascular and Metabolic Medicine, School of MedicineUniversity of LeedsLeedsUK
| |
Collapse
|
6
|
Krilaviciute A, Lakes J, Radtke J, Herkommer K, Gschwend J, Peters I, Kuczyk M, Koerber S, Debus J, Kristiansen G, Schimmöller L, Antoch G, Makowski M, Wacker F, Schlemmer H, Benner A, Giesel F, Siener R, Arsov C, Hadaschik B, Kaaks R, Becker N, Albers P. Digital Rectal Examination (DRE) is not useful as a solitary screening tool for prostate cancer in young men – Results from the PROBASE trial. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00939-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
7
|
Karamatic Crew V, Tilley LA, Satchwell TJ, AlSubhi SA, Jones B, Spring FA, Walser PJ, Martins Freire C, Murciano N, Rotordam MG, Woestmann SJ, Hamed M, Alradwan R, AlKhrousey M, Skidmore I, Lewis S, Hussain S, Jackson J, Latham T, Kilby MD, Lester W, Becker N, Rapedius M, Toye AM, Thornton NM. Missense mutations in PIEZO1, which encodes the Piezo1 mechanosensor protein, define Er red blood cell antigens. Blood 2023; 141:135-146. [PMID: 36122374 PMCID: PMC10644042 DOI: 10.1182/blood.2022016504] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 07/28/2022] [Accepted: 08/15/2022] [Indexed: 01/17/2023] Open
Abstract
Despite the identification of the high-incidence red cell antigen Era nearly 40 years ago, the molecular background of this antigen, together with the other 2 members of the Er blood group collection, has yet to be elucidated. Whole exome and Sanger sequencing of individuals with serologically defined Er alloantibodies identified several missense mutations within the PIEZO1 gene, encoding amino acid substitutions within the extracellular domain of the Piezo1 mechanosensor ion channel. Confirmation of Piezo1 as the carrier molecule for the Er blood group antigens was demonstrated using immunoprecipitation, CRISPR/Cas9-mediated gene knockout, and expression studies in an erythroblast cell line. We report the molecular bases of 5 Er blood group antigens: the recognized Era, Erb, and Er3 antigens and 2 novel high-incidence Er antigens, described here as Er4 and Er5, establishing a new blood group system. Anti-Er4 and anti-Er5 are implicated in severe hemolytic disease of the fetus and newborn. Demonstration of Piezo1, present at just a few hundred copies on the surface of the red blood cell, as the site of a new blood group system highlights the potential antigenicity of even low-abundance membrane proteins and contributes to our understanding of the in vivo characteristics of this important and widely studied protein in transfusion biology and beyond.
Collapse
Affiliation(s)
- Vanja Karamatic Crew
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, United Kingdom
| | - Louise A. Tilley
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, United Kingdom
| | - Timothy J. Satchwell
- School of Biochemistry, University of Bristol, Bristol, United Kingdom
- National Institute for Health Research Blood and Transplant Research Unit in Red Blood Cell Products, University of Bristol, Bristol, United Kingdom
- Bristol Institute of Transfusion Sciences, NHS Blood and Transplant, Bristol, United Kingdom
| | - Samah A. AlSubhi
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, United Kingdom
- School of Biochemistry, University of Bristol, Bristol, United Kingdom
- Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia
| | - Benjamin Jones
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, United Kingdom
| | - Frances A. Spring
- National Institute for Health Research Blood and Transplant Research Unit in Red Blood Cell Products, University of Bristol, Bristol, United Kingdom
- Bristol Institute of Transfusion Sciences, NHS Blood and Transplant, Bristol, United Kingdom
| | - Piers J. Walser
- Clinical Biotechnology Centre, NHS Blood and Transplant, Bristol, United Kingdom
| | | | - Nicoletta Murciano
- Theoretical Medicine and Biosciences, Saarland University, Homburg, Germany
- Research and Development, Nanion Technologies, Munich, Germany
| | | | | | | | | | | | - Ian Skidmore
- Red Cell Immunohaematology, NHS Blood and Transplant, Birmingham, United Kingdom
| | - Sarah Lewis
- Red Cell Immunohaematology, NHS Blood and Transplant, Birmingham, United Kingdom
| | - Shimon Hussain
- Red Cell Immunohaematology, NHS Blood and Transplant, Birmingham, United Kingdom
| | - Jane Jackson
- Haematology Department at Birmingham Women’s Hospital, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom
| | - Tom Latham
- NHS Blood and Transplant, Bristol, United Kingdom
| | - Mark D. Kilby
- College of Medical & Dental Sciences, University of Birmingham, Birmingham, United Kingdom
- Fetal Medicine Centre, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom
| | - William Lester
- Haematology Department at Birmingham Women’s Hospital, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom
| | - Nadine Becker
- Research and Development, Nanion Technologies, Munich, Germany
| | - Markus Rapedius
- Research and Development, Nanion Technologies, Munich, Germany
| | - Ashley M. Toye
- School of Biochemistry, University of Bristol, Bristol, United Kingdom
- National Institute for Health Research Blood and Transplant Research Unit in Red Blood Cell Products, University of Bristol, Bristol, United Kingdom
- Bristol Institute of Transfusion Sciences, NHS Blood and Transplant, Bristol, United Kingdom
| | - Nicole M. Thornton
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, United Kingdom
| |
Collapse
|
8
|
Flormann D, Qiao M, Murciano N, Iacono G, Darras A, Hof S, Recktenwald SM, Rotordam MG, Becker N, Geisel J, Wagner C, von Lindern M, Akker E, Kaestner L. Transient receptor potential channel vanilloid type 2 in red cells of cannabis consumer. Am J Hematol 2022; 97:E180-E183. [PMID: 35179248 DOI: 10.1002/ajh.26509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2021] [Revised: 02/07/2022] [Accepted: 02/10/2022] [Indexed: 11/09/2022]
Affiliation(s)
- Daniel Flormann
- Experimental Physics Saarland University Saarbrücken Germany
| | - Min Qiao
- Experimental Physics Saarland University Saarbrücken Germany
- Theoretical Medicine and Biosciences Saarland University Homburg Germany
| | - Nicoletta Murciano
- Theoretical Medicine and Biosciences Saarland University Homburg Germany
- Research and Development Nanion Technologies Munich Germany
| | - Giulia Iacono
- Department of Hematopoiesis Sanquin Research Amsterdam The Netherlands
- Landsteiner Laboratory Amsterdam UMC, University of Amsterdam Amsterdam The Netherlands
| | - Alexis Darras
- Experimental Physics Saarland University Saarbrücken Germany
| | - Sebastian Hof
- Experimental Physics Saarland University Saarbrücken Germany
- Theoretical Medicine and Biosciences Saarland University Homburg Germany
| | | | - Maria Giustina Rotordam
- Theoretical Medicine and Biosciences Saarland University Homburg Germany
- Research and Development Nanion Technologies Munich Germany
| | - Nadine Becker
- Research and Development Nanion Technologies Munich Germany
| | - Jürgen Geisel
- Clinical Chemistry and Laboratory Medicine Saarland University Hospital Homburg Germany
| | - Christian Wagner
- Experimental Physics Saarland University Saarbrücken Germany
- Physics and Materials Science Research Unit University of Luxembourg Luxembourg City Luxembourg
| | - Marieke von Lindern
- Department of Hematopoiesis Sanquin Research Amsterdam The Netherlands
- Landsteiner Laboratory Amsterdam UMC, University of Amsterdam Amsterdam The Netherlands
| | - Emile Akker
- Department of Hematopoiesis Sanquin Research Amsterdam The Netherlands
- Landsteiner Laboratory Amsterdam UMC, University of Amsterdam Amsterdam The Netherlands
| | - Lars Kaestner
- Experimental Physics Saarland University Saarbrücken Germany
- Theoretical Medicine and Biosciences Saarland University Homburg Germany
| |
Collapse
|
9
|
Ridley J, Manyweathers S, Tang R, Goetze T, Becker N, Rinke-Weiß I, Kirby R, Obergrussberger A, Rogers M. Development of ASIC1a ligand-gated ion channel drug screening assays across multiple automated patch clamp platforms. Front Mol Neurosci 2022; 15:982689. [PMID: 36340694 PMCID: PMC9629855 DOI: 10.3389/fnmol.2022.982689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Accepted: 09/12/2022] [Indexed: 02/05/2023] Open
Abstract
Human acid-sensing ion channels (ASIC) are ligand-gated ionotropic receptors expressed widely in peripheral tissues as well as sensory and central neurons and implicated in detection of inflammation, tissue injury, and hypoxia-induced acidosis. This makes ASIC channels promising targets for drug discovery in oncology, pain and ischemia, and several modulators have progressed into clinical trials. We describe the use of hASIC1a as a case study for the development and validation of low, medium and high throughput automated patch clamp (APC) assays suitable for the screening and mechanistic profiling of new ligands for this important class of ligand-gated ion channel. Initial efforts to expand on previous manual patch work describing an endogenous hASIC1a response in HEK cells were thwarted by low current expression and unusual pharmacology, so subsequent work utilized stable hASIC1a CHO cell lines. Ligand-gated application protocols and screening assays on the Patchliner, QPatch 48, and SyncroPatch 384 were optimized and validated based on pH activation and nM-μM potency of reference antagonists (e.g., Amiloride, Benzamil, Memantine, Mambalgin-3, A-317567, PcTx1). By optimizing single and stacked pipette tip applications available on each APC platform, stable pH-evoked currents during multiple ligand applications enabled cumulative EC50 and IC50 determinations with minimized receptor desensitization. Finally, we successfully demonstrated for the first time on an APC platform the ability to use current clamp to implement the historical technique of input resistance tracking to measure ligand-gated changes in membrane conductance on the Patchliner platform.
Collapse
Affiliation(s)
- John Ridley
- Metrion Biosciences Ltd., Cambridge, United Kingdom
| | | | - Raymond Tang
- Metrion Biosciences Ltd., Cambridge, United Kingdom
| | - Tom Goetze
- Nanion Technologies GmbH, Munich, Germany
| | | | | | - Robert Kirby
- Metrion Biosciences Ltd., Cambridge, United Kingdom
| | | | - Marc Rogers
- Metrion Biosciences Ltd., Cambridge, United Kingdom
- *Correspondence: Marc Rogers,
| |
Collapse
|
10
|
Buks R, Dagher T, Rotordam MG, Monedero Alonso D, Cochet S, Gautier EF, Chafey P, Cassinat B, Kiladjian JJ, Becker N, Plo I, Egée S, El Nemer W. Altered Ca 2+ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis. Cells 2021; 11:49. [PMID: 35011611 PMCID: PMC8750512 DOI: 10.3390/cells11010049] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2021] [Revised: 12/20/2021] [Accepted: 12/21/2021] [Indexed: 02/07/2023] Open
Abstract
Over 95% of Polycythemia Vera (PV) patients carry the V617F mutation in the tyrosine kinase Janus kinase 2 (JAK2), resulting in uncontrolled erythroid proliferation and a high risk of thrombosis. Using mass spectrometry, we analyzed the RBC membrane proteome and showed elevated levels of multiple Ca2+ binding proteins as well as endoplasmic-reticulum-residing proteins in PV RBC membranes compared with RBC membranes from healthy individuals. In this study, we investigated the impact of JAK2V617F on (1) calcium homeostasis and RBC ion channel activity and (2) protein expression and sorting during terminal erythroid differentiation. Our data from automated patch-clamp show modified calcium homeostasis in PV RBCs and cell lines expressing JAK2V617F, with a functional impact on the activity of the Gárdos channel that could contribute to cellular dehydration. We show that JAK2V617F could play a role in organelle retention during the enucleation step of erythroid differentiation, resulting in modified whole cell proteome in reticulocytes and RBCs in PV patients. Given the central role that calcium plays in the regulation of signaling pathways, our study opens new perspectives to exploring the relationship between JAK2V617F, calcium homeostasis, and cellular abnormalities in myeloproliferative neoplasms, including cellular interactions in the bloodstream in relation to thrombotic events.
Collapse
Affiliation(s)
- Ralfs Buks
- BIGR, UMR_S1134, Inserm, Université de Paris, F-75015 Paris, France; (R.B.); (S.C.)
- Institut National de la Transfusion Sanguine, F-75015 Paris, France
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
| | - Tracy Dagher
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- U1287, Inserm, Université Paris-Saclay, Gustave Roussy, F-94800 Villejuif, France
| | - Maria Giustina Rotordam
- Nanion Technologies GmbH, 80339 Munich, Germany; (M.G.R.); (N.B.)
- Theoretical Medicine and Biosciences, Medical Faculty, Saarland University, Kirrbergerstr. 100, DE-66424 Homburg, Germany
| | - David Monedero Alonso
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- Sorbonne Université, CNRS, UMR LBI2M, Station Biologique de Roscoff SBR, F-29680 Roscoff, France
| | - Sylvie Cochet
- BIGR, UMR_S1134, Inserm, Université de Paris, F-75015 Paris, France; (R.B.); (S.C.)
- Institut National de la Transfusion Sanguine, F-75015 Paris, France
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
| | - Emilie-Fleur Gautier
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- Institut Imagine-INSERM U1163, Necker Hospital, Université de Paris, F-75015 Paris, France
- Proteomics Platform 3P5, Université de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104 Paris, France;
| | - Philippe Chafey
- Proteomics Platform 3P5, Université de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104 Paris, France;
| | - Bruno Cassinat
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- IRSL, U1131, INSERM, Université de Paris, F-75010 Paris, France
- Hôpital Saint-Louis, Laboratoire de Biologie Cellulaire, AP-HP, F-75010 Paris, France
| | - Jean-Jacques Kiladjian
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- IRSL, U1131, INSERM, Université de Paris, F-75010 Paris, France
- Centre d’Investigations Cliniques, Hôpital Saint-Louis, Université de Paris, F-75010 Paris, France
| | - Nadine Becker
- Nanion Technologies GmbH, 80339 Munich, Germany; (M.G.R.); (N.B.)
| | - Isabelle Plo
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- U1287, Inserm, Université Paris-Saclay, Gustave Roussy, F-94800 Villejuif, France
| | - Stéphane Egée
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- Sorbonne Université, CNRS, UMR LBI2M, Station Biologique de Roscoff SBR, F-29680 Roscoff, France
| | - Wassim El Nemer
- BIGR, UMR_S1134, Inserm, Université de Paris, F-75015 Paris, France; (R.B.); (S.C.)
- Institut National de la Transfusion Sanguine, F-75015 Paris, France
- Laboratoire d’Excellence GR-Ex, F-75015 Paris, France; (T.D.); (D.M.A.); (E.-F.G.); (B.C.); (J.-J.K.); (I.P.); (S.E.)
- Etablissement Français du Sang PACA-Corse, F-13005Marseille, France
- Aix Marseille Univ, EFS, CNRS, ADES, “Biologie des Groupes Sanguins”, F-13005 Marseille, France
| |
Collapse
|
11
|
Obergrussberger A, Rinke-Weiß I, Goetze TA, Rapedius M, Brinkwirth N, Becker N, Rotordam MG, Hutchison L, Madau P, Pau D, Dalrymple D, Braun N, Friis S, Pless SA, Fertig N. The suitability of high throughput automated patch clamp for physiological applications. J Physiol 2021; 600:277-297. [PMID: 34555195 DOI: 10.1113/jp282107] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2021] [Accepted: 09/16/2021] [Indexed: 01/18/2023] Open
Abstract
Although automated patch clamp (APC) devices have been around for many years and have become an integral part of many aspects of drug discovery, high throughput instruments with gigaohm seal data quality are relatively new. Experiments where a large number of compounds are screened against ion channels are ideally suited to high throughput APC, particularly when the amount of compound available is low. Here we evaluate different APC approaches using a variety of ion channels and screening settings. We have performed a screen of 1920 compounds on GluN1/GluN2A NMDA receptors for negative allosteric modulation using both the SyncroPatch 384 and FLIPR. Additionally, we tested the effect of 36 arthropod venoms on NaV 1.9 using a single 384-well plate on the SyncroPatch 384. As an example for mutant screening, a range of acid-sensing ion channel variants were tested and the success rate increased through fluorescence-activated cell sorting (FACS) prior to APC experiments. Gigaohm seal data quality makes the 384-format accessible to recording of primary and stem cell-derived cells on the SyncroPatch 384. We show recordings in voltage and current clamp modes of stem cell-derived cardiomyocytes. In addition, the option of intracellular solution exchange enabled investigations into the effects of intracellular Ca2+ and cAMP on TRPC5 and HCN2 currents, respectively. Together, these data highlight the broad applicability and versatility of APC platforms and also outlines some limitations of the approach. KEY POINTS: High throughput automated patch clamp (APC) can be used for a variety of applications involving ion channels. Lower false positive rates were achieved using automated patch clamp versus a fluorometric imaging plate reader (FLIPR) in a high throughput compound screen against NMDA receptors. Genetic variants and mutations can be screened on a single 384-well plate to reduce variability of experimental parameters. Intracellular solution can be perfused to investigate effects of ions and second messenger systems without the need for excised patches. Primary cells and stem cell-derived cells can be used on high throughput APC with reasonable success rates for cell capture, voltage clamp measurements and action potential recordings in current clamp mode.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Nina Braun
- Department of Drug Design and Pharmacology, University of Copenhagen, Denmark
| | | | - Stephan A Pless
- Department of Drug Design and Pharmacology, University of Copenhagen, Denmark
| | | |
Collapse
|
12
|
Rotordam MG, Obergrussberger A, Brinkwirth N, Takasuna K, Becker N, Horváth A, Goetze TA, Rapedius M, Furukawa H, Hasegawa Y, Oka T, Fertig N, Stoelzle-Feix S. Reliable identification of cardiac conduction abnormalities in drug discovery using automated patch clamp II: Best practices for Nav1.5 peak current in a high throughput screening environment. J Pharmacol Toxicol Methods 2021; 112:107125. [PMID: 34500078 DOI: 10.1016/j.vascn.2021.107125] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 07/16/2021] [Accepted: 09/03/2021] [Indexed: 12/19/2022]
Abstract
INTRODUCTION For reliable identification of cardiac safety risk, compounds should be screened for activity on cardiac ion channels in addition to hERG, including NaV1.5 and CaV1.2. We identified different parameters that might affect IC50s of compounds on NaV1.5 peak and late currents recorded using automated patch clamp (APC) and suggest outlines for best practices. METHODS APC instruments SyncroPatch 384 and Patchliner were used to record NaV1.5 peak and late current. Up to 24 CiPA compounds were used to investigate effects of voltage protocol, holding potential (-80 mV or - 95 mV) and temperature (23 ± 1 °C or 36 ± 1 °C) on IC50 values on hNaV1.5 overexpressed in HEK or CHO cells either as frozen cells or running cultures. RESULTS The IC50s of 18 compounds on the NaV1.5 peak current recorded on the SyncroPatch 384 using the CiPA step-ramp protocol correlated well with the literature. The use of frozen or cultured cells did not affect IC50s but voltage protocol and holding potential did cause differences in IC50 values. Temperature can affect Vhalf of inactivation and also compound potency. A compound incubation time of 5-6 min was sufficient for most compounds, however slow acting compounds such as terfenadine required longer to reach maximum effect. DISCUSSION We conclude that holding potential, voltage protocol and temperature can affect IC50 values and recommend the use of the CiPA step-ramp protocol at physiological temperature to record NaV1.5 peak and late currents for cardiac safety. Further recommendations include: a minimum compound incubation time of 5 min, a replicate number of 4 and the use of positive and negative controls for reliable IC50s.
Collapse
|
13
|
Rogers M, Rotordam MG, Rapedius M, Kirby R, Jinat A, Obergrussberger A, Becker N, George M, Fertig N. The NaV1.5 late current in WT and Nav1.5-ΔKPQ mutant channels: An automated patch clamp LQT3 electrophysiological assay comparison. J Pharmacol Toxicol Methods 2021. [DOI: 10.1016/j.vascn.2021.106966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
14
|
Bruggemann A, Goetze TA, Horváth A, Rinke I, Becker N, Obergrussberger A, Focke L, Wehmeier O, Schwandner R, Fertig N. Activation and Inhibition of Assay-Ready TRPA1 and TRPV Cells: An Automated Patch Clamp Study. Biophys J 2021. [DOI: 10.1016/j.bpj.2020.11.2105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
15
|
Cho G, Kwon H, Kim D, Horvath A, Becker N, Juhasz K, Dragicevic E, Stoelzle-Feix S. Evaluation of human iPS cell-derived cardiomyocytes in high-throughput toxicity screening applications. J Pharmacol Toxicol Methods 2020. [DOI: 10.1016/j.vascn.2020.106794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Brinkwirth N, Takasuna K, Doi M, Becker N, Obergrussberger A, Friis S, Furukawa H, Hasegawa Y, Oka T, Ohtsuki A, Fertig N, Stoelzle-Feix S. Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment. J Pharmacol Toxicol Methods 2020; 105:106884. [DOI: 10.1016/j.vascn.2020.106884] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 05/20/2020] [Accepted: 05/29/2020] [Indexed: 11/26/2022]
|
17
|
Stoelzle-Feix S, Brinkwirth N, Becker N, Haarmann C, Knox R, Hampl M, George M, Vogel M, Haedo R, Fertig N. Reliable identification of hERG liability in drug discovery by automated patch clamp. J Pharmacol Toxicol Methods 2020. [DOI: 10.1016/j.vascn.2020.106743] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
18
|
Han X, Samieegohar M, Ridder BJ, Wu WW, Randolph A, Tran P, Sheng J, Stoelzle-Feix S, Brinkwirth N, Rotordam MG, Becker N, Friis S, Rapedius M, Goetze TA, Strassmaier T, Okeyo G, Kramer J, Kuryshev Y, Wu C, Strauss DG, Li Z. A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA model. J Pharmacol Toxicol Methods 2020; 105:106890. [PMID: 32574700 DOI: 10.1016/j.vascn.2020.106890] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Revised: 06/08/2020] [Accepted: 06/11/2020] [Indexed: 02/01/2023]
Abstract
INTRODUCTION In response to the ongoing shift of the regulatory cardiac safety paradigm, a recent White Paper proposed general principles for developing and implementing proarrhythmia risk prediction models. These principles included development strategies to validate models, and implementation strategies to ensure a model developed by one lab can be used by other labs in a consistent manner in the presence of lab-to-lab experimental variability. While the development strategies were illustrated through the validation of the model under the Comprehensive In vitro Proarrhythmia Assay (CiPA), the implementation strategies have not been adopted yet. METHODS The proposed implementation strategies were applied to the CiPA model by performing a sensitivity analysis to identify a subset of calibration drugs that were most critical in determining the classification thresholds for proarrhythmia risk prediction. RESULTS The selected calibration drugs were able to recapitulate classification thresholds close to those calculated from the full list of CiPA drugs. Using an illustrative dataset it was shown that a new lab could use these calibration drugs to establish its own classification thresholds (lab-specific calibration), and verify that the model prediction accuracy in the new lab is comparable to that in the original lab where the model was developed (lab-specific validation). DISCUSSION This work used the CiPA model as an example to illustrate how to adopt the proposed model implementation strategies to select calibration drugs and perform lab-specific calibration and lab-specific validation. Generic in nature, these strategies could be generally applied to different proarrhythmia risk prediction models using various experimental systems under the new paradigm.
Collapse
Affiliation(s)
- Xiaomei Han
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Mohammadreza Samieegohar
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Bradley J Ridder
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Wendy W Wu
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Aaron Randolph
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Phu Tran
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Jiansong Sheng
- CiPA LAB, 900 Clopper Rd, Suite 130, Gaithersburg, MD 20878, United States
| | | | - Nina Brinkwirth
- Nanion Technologies Munich, Ganghoferstrasse 70A, Munich, Germany
| | | | - Nadine Becker
- Nanion Technologies Munich, Ganghoferstrasse 70A, Munich, Germany
| | - Søren Friis
- Nanion Technologies Munich, Ganghoferstrasse 70A, Munich, Germany
| | - Markus Rapedius
- Nanion Technologies Munich, Ganghoferstrasse 70A, Munich, Germany
| | - Tom A Goetze
- Nanion Technologies Munich, Ganghoferstrasse 70A, Munich, Germany
| | - Tim Strassmaier
- Nanion Technologies USA, 1 Naylon Place, Suite C, Livingston, NJ 07039, United States
| | - George Okeyo
- Nanion Technologies USA, 1 Naylon Place, Suite C, Livingston, NJ 07039, United States
| | - James Kramer
- Charles River Laboratories, 14656 Neo Parkway, Cleveland, OH 44128, United States
| | - Yuri Kuryshev
- Charles River Laboratories, 14656 Neo Parkway, Cleveland, OH 44128, United States
| | - Caiyun Wu
- Charles River Laboratories, 14656 Neo Parkway, Cleveland, OH 44128, United States
| | - David G Strauss
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Zhihua Li
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States.
| |
Collapse
|
19
|
Ridder BJ, Leishman DJ, Bridgland-Taylor M, Samieegohar M, Han X, Wu WW, Randolph A, Tran P, Sheng J, Danker T, Lindqvist A, Konrad D, Hebeisen S, Polonchuk L, Gissinger E, Renganathan M, Koci B, Wei H, Fan J, Levesque P, Kwagh J, Imredy J, Zhai J, Rogers M, Humphries E, Kirby R, Stoelzle-Feix S, Brinkwirth N, Rotordam MG, Becker N, Friis S, Rapedius M, Goetze TA, Strassmaier T, Okeyo G, Kramer J, Kuryshev Y, Wu C, Himmel H, Mirams GR, Strauss DG, Bardenet R, Li Z. Corrigendum to "A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm" [Toxicology and Applied Pharmacology volume 394C (2020) 114961]. Toxicol Appl Pharmacol 2020; 395:114983. [PMID: 32247767 PMCID: PMC7355225 DOI: 10.1016/j.taap.2020.114983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Bradley J Ridder
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Derek J Leishman
- Department of Toxicology and Pathology, Eli Lilly and Company, Indianapolis, IN, USA
| | - Matthew Bridgland-Taylor
- Clinical Pharmacology & Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
| | - Mohammadreza Samieegohar
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Xiaomei Han
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Wendy W Wu
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Aaron Randolph
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Phu Tran
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Jiansong Sheng
- CiPA LAB, 900 Clopper Rd, Suite 130, Gaithersburg, MD 20878, USA
| | - Timm Danker
- NMI-TT GmbH, Markwiesenstr. 55, 72770 Reutlingen, Germany
| | | | - Daniel Konrad
- B'SYS GmbH, The Ion Channel Company, Benkenstrasse 254, CH-4108 Witterswil, Switzerland
| | - Simon Hebeisen
- B'SYS GmbH, The Ion Channel Company, Benkenstrasse 254, CH-4108 Witterswil, Switzerland
| | - Liudmila Polonchuk
- F. Hoffmann-La Roche AG, F. Hoffmann-La Roche Ltd., Bldg. 73 / R. 103b Grenzacherstrasse, 124, CH-4070, Basel, Switzerland
| | - Evgenia Gissinger
- F. Hoffmann-La Roche AG, F. Hoffmann-La Roche Ltd., Bldg. 73 / R. 103b Grenzacherstrasse, 124, CH-4070, Basel, Switzerland
| | | | - Bryan Koci
- Eurofins Scientific, Eurofins Discovery, 6 Research Park Drive, St. Charles, MO 63304, USA
| | - Haiyang Wei
- Eurofins Scientific, Eurofins Discovery, 6 Research Park Drive, St. Charles, MO 63304, USA
| | - Jingsong Fan
- Bristol-Myers Squibb Company, Discovery Toxicology, Bristol-Myers Squibb, 3551 Lawrenceville, Princeton Rd, Lawrence Township, NJ 08648, USA
| | - Paul Levesque
- Bristol-Myers Squibb Company, Discovery Toxicology, Bristol-Myers Squibb, 3551 Lawrenceville, Princeton Rd, Lawrence Township, NJ 08648, USA
| | - Jae Kwagh
- Bristol-Myers Squibb Company, Discovery Toxicology, Bristol-Myers Squibb, 3551 Lawrenceville, Princeton Rd, Lawrence Township, NJ 08648, USA
| | | | - Jin Zhai
- Merck & Co., Inc., Kenilworth, NJ, USA
| | - Marc Rogers
- Metrion Biosciences Limited, Riverside 3, Suite 1, Granta Park, Great Abington, Cambridge CB21 6AD, United Kingdom
| | - Edward Humphries
- Metrion Biosciences Limited, Riverside 3, Suite 1, Granta Park, Great Abington, Cambridge CB21 6AD, United Kingdom
| | - Robert Kirby
- Metrion Biosciences Limited, Riverside 3, Suite 1, Granta Park, Great Abington, Cambridge CB21 6AD, United Kingdom
| | | | - Nina Brinkwirth
- Nanion Technologies Munich, Ganghoferstrasse 70A, 80339 Munich, Germany
| | | | - Nadine Becker
- Nanion Technologies Munich, Ganghoferstrasse 70A, 80339 Munich, Germany
| | - Søren Friis
- Nanion Technologies Munich, Ganghoferstrasse 70A, 80339 Munich, Germany
| | - Markus Rapedius
- Nanion Technologies Munich, Ganghoferstrasse 70A, 80339 Munich, Germany
| | - Tom A Goetze
- Nanion Technologies Munich, Ganghoferstrasse 70A, 80339 Munich, Germany
| | - Tim Strassmaier
- Nanion Technologies USA, 1 Naylon Place, Suite C, Livingston, NJ 07039, USA
| | - George Okeyo
- Nanion Technologies USA, 1 Naylon Place, Suite C, Livingston, NJ 07039, USA
| | - James Kramer
- Charles River Laboratories, 14656 Neo Parkway, Cleveland, OH 44128, USA
| | - Yuri Kuryshev
- Charles River Laboratories, 14656 Neo Parkway, Cleveland, OH 44128, USA
| | - Caiyun Wu
- Charles River Laboratories, 14656 Neo Parkway, Cleveland, OH 44128, USA
| | - Herbert Himmel
- Bayer AG, RD-TS-TOX-SP-SPL1, Aprather Weg 18a, 42096 Wuppertal, Germany
| | - Gary R Mirams
- Centre for Mathematical Medicine & Biology, School of Mathematical Sciences, University of Nottingham, Nottingham, United Kingdom
| | - David G Strauss
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Remi Bardenet
- Université de Lille, CNRS, Centrale Lille, UMR 9189 - CRIStAL, Villeneuve d'Ascq, France
| | - Zhihua Li
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA.
| |
Collapse
|
20
|
Ridder BJ, Leishman DJ, Bridgland-Taylor M, Samieegohar M, Han X, Wu WW, Randolph A, Tran P, Sheng J, Danker T, Lindqvist A, Konrad D, Hebeisen S, Polonchuk L, Gissinger E, Renganathan M, Koci B, Wei H, Fan J, Levesque P, Kwagh J, Imredy J, Zhai J, Rogers M, Humphries E, Kirby R, Stoelzle-Feix S, Brinkwirth N, Rotordam MG, Becker N, Friis S, Rapedius M, Goetze TA, Strassmaier T, Okeyo G, Kramer J, Kuryshev Y, Wu C, Himmel H, Mirams GR, Strauss DG, Bardenet R, Li Z. A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm. Toxicol Appl Pharmacol 2020; 394:114961. [PMID: 32209365 PMCID: PMC7166077 DOI: 10.1016/j.taap.2020.114961] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Revised: 02/14/2020] [Accepted: 03/19/2020] [Indexed: 12/13/2022]
Abstract
Introduction hERG block potency is widely used to calculate a drug's safety margin against its torsadogenic potential. Previous studies are confounded by use of different patch clamp electrophysiology protocols and a lack of statistical quantification of experimental variability. Since the new cardiac safety paradigm being discussed by the International Council for Harmonisation promotes a tighter integration of nonclinical and clinical data for torsadogenic risk assessment, a more systematic approach to estimate the hERG block potency and safety margin is needed. Methods A cross-industry study was performed to collect hERG data on 28 drugs with known torsadogenic risk using a standardized experimental protocol. A Bayesian hierarchical modeling (BHM) approach was used to assess the hERG block potency of these drugs by quantifying both the inter-site and intra-site variability. A modeling and simulation study was also done to evaluate protocol-dependent changes in hERG potency estimates. Results A systematic approach to estimate hERG block potency is established. The impact of choosing a safety margin threshold on torsadogenic risk evaluation is explored based on the posterior distributions of hERG potency estimated by this method. The modeling and simulation results suggest any potency estimate is specific to the protocol used. Discussion This methodology can estimate hERG block potency specific to a given voltage protocol. The relationship between safety margin thresholds and torsadogenic risk predictivity suggests the threshold should be tailored to each specific context of use, and safety margin evaluation may need to be integrated with other information to form a more comprehensive risk assessment. hERG potency/safety margin is a widely used nonclinical cardiac safety strategy. A new regulatory paradigm promotes the integration of nonclinical and clinical data. Lack of uncertainty quantification hindered using hERG potency in the new paradigm. A systematic method was established to address this limitation. Analysis supports using different safety margin thresholds in different context.
Collapse
Affiliation(s)
- Bradley J Ridder
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Derek J Leishman
- Department of Toxicology and Pathology, Eli Lilly and Company, Indianapolis, IN, USA
| | | | - Mohammadreza Samieegohar
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Xiaomei Han
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Wendy W Wu
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Aaron Randolph
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Phu Tran
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Jiansong Sheng
- CiPA LAB, 900 Clopper Rd, Suite 130, Gaithersburg, MD 20878, USA
| | - Timm Danker
- NMI-TT GmbH, Markwiesenstr. 55, 72770 Reutlingen, Germany
| | | | - Daniel Konrad
- B'SYS GmbH, The Ion Channel Company, Benkenstrasse 254, CH-4108, Witterswil, Switzerland
| | - Simon Hebeisen
- B'SYS GmbH, The Ion Channel Company, Benkenstrasse 254, CH-4108, Witterswil, Switzerland
| | - Liudmila Polonchuk
- F. Hoffmann-La Roche AG, F. Hoffmann-La Roche Ltd Bldg. 73/R. 103b Grenzacherstrasse, 124, CH-4070 Basel, Switzerland
| | - Evgenia Gissinger
- F. Hoffmann-La Roche AG, F. Hoffmann-La Roche Ltd Bldg. 73/R. 103b Grenzacherstrasse, 124, CH-4070 Basel, Switzerland
| | | | - Bryan Koci
- Eurofins Scientific, Eurofins Discovery, 6 Research Park Drive, St. Charles, MO 63304, USA
| | - Haiyang Wei
- Eurofins Scientific, Eurofins Discovery, 6 Research Park Drive, St. Charles, MO 63304, USA
| | - Jingsong Fan
- Bristol-Myers Squibb Company, Discovery Toxicology, Bristol-Myers Squibb, 3551 Lawrenceville, Princeton Rd, Lawrence Township, NJ 08648, USA
| | - Paul Levesque
- Bristol-Myers Squibb Company, Discovery Toxicology, Bristol-Myers Squibb, 3551 Lawrenceville, Princeton Rd, Lawrence Township, NJ 08648, USA
| | - Jae Kwagh
- Bristol-Myers Squibb Company, Discovery Toxicology, Bristol-Myers Squibb, 3551 Lawrenceville, Princeton Rd, Lawrence Township, NJ 08648, USA
| | | | - Jin Zhai
- Merck & Co., Inc, Kenilworth, NJ, USA
| | - Marc Rogers
- Metrion Biosciences Limited, Riverside 3, Suite 1, Granta Park, Great Abington, Cambridge CB21, 6AD, United Kingdom
| | - Edward Humphries
- Metrion Biosciences Limited, Riverside 3, Suite 1, Granta Park, Great Abington, Cambridge CB21, 6AD, United Kingdom
| | - Robert Kirby
- Metrion Biosciences Limited, Riverside 3, Suite 1, Granta Park, Great Abington, Cambridge CB21, 6AD, United Kingdom
| | | | - Nina Brinkwirth
- Nanion Technologies Munich, Ganghoferstrasse 70A, 80339 Munich, Germany
| | | | - Nadine Becker
- Nanion Technologies Munich, Ganghoferstrasse 70A, 80339 Munich, Germany
| | - Søren Friis
- Nanion Technologies Munich, Ganghoferstrasse 70A, 80339 Munich, Germany
| | - Markus Rapedius
- Nanion Technologies Munich, Ganghoferstrasse 70A, 80339 Munich, Germany
| | - Tom A Goetze
- Nanion Technologies Munich, Ganghoferstrasse 70A, 80339 Munich, Germany
| | - Tim Strassmaier
- Nanion Technologies, USA, 1 Naylon Place, Suite C, Livingston, NJ 07039, USA
| | - George Okeyo
- Nanion Technologies, USA, 1 Naylon Place, Suite C, Livingston, NJ 07039, USA
| | - James Kramer
- Charles River Laboratories, 14656 Neo Parkway, Cleveland, OH 44128, USA
| | - Yuri Kuryshev
- Charles River Laboratories, 14656 Neo Parkway, Cleveland, OH 44128, USA
| | - Caiyun Wu
- Charles River Laboratories, 14656 Neo Parkway, Cleveland, OH 44128, USA
| | - Herbert Himmel
- Bayer AG, RD-TS-TOX-SP-SPL1, Aprather Weg 18a, 42096 Wuppertal, Germany
| | - Gary R Mirams
- Centre for Mathematical Medicine & Biology, School of Mathematical Sciences, University of Nottingham, Nottingham, United Kingdom
| | - David G Strauss
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
| | - Rémi Bardenet
- Université de Lille, CNRS, Centrale Lille, UMR 9189 - CRIStAL, Villeneuve d'Ascq, France
| | - Zhihua Li
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA.
| |
Collapse
|
21
|
Costantin JL, Strassmaier T, Rotordam GM, Goetze T, Becker N, Obergrussberger A, Bruggemann A, George M, Fertig N. Kinetic and Pharmacological Properties of P2X3 and P2X2/3 Receptors. Biophys J 2020. [DOI: 10.1016/j.bpj.2019.11.787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
22
|
Becker N, Horváth A, De Boer T, Fabbri A, Grad C, Fertig N, George M, Obergrussberger A. Automated Dynamic Clamp for Simulation of I
K1
in Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Real Time Using Patchliner Dynamite
8. ACTA ACUST UNITED AC 2019; 88:e70. [DOI: 10.1002/cpph.70] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
| | | | - Teun De Boer
- Department of Medical PhysiologyUniversity Medical Center Utrecht Utrecht The Netherlands
| | - Alan Fabbri
- Department of Medical PhysiologyUniversity Medical Center Utrecht Utrecht The Netherlands
| | | | | | | | | |
Collapse
|
23
|
Bhatia A, Husaini M, Lin C, LeClair J, De Togni E, Becker N, Scott A, Terng M, Acevedo-Cintron J, Schilling J. How Dynamic are Hemodynamics?: Short-Term Changes in Hemodynamic Measures and Indices among Heart Failure Patients. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
24
|
Bruggemann A, Rotordam GM, Becker N, Fertig N, Bianchi P, Rapedius M, Kaestner L. A Novel Gain of Function Mutation of Piezo-1 is Investigated in Red Blood Cells by High-Throughput Patch Clamp. Biophys J 2019. [DOI: 10.1016/j.bpj.2018.11.1340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
25
|
Schäfer SK, Becker N, King L, Horsch A, Michael T. The relationship between sense of coherence and post-traumatic stress: a meta-analysis. Eur J Psychotraumatol 2019; 10:1562839. [PMID: 30693079 PMCID: PMC6338278 DOI: 10.1080/20008198.2018.1562839] [Citation(s) in RCA: 71] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Revised: 12/04/2018] [Accepted: 12/07/2018] [Indexed: 01/23/2023] Open
Abstract
Background: Antonovsky's concept of sense of coherence (SOC) - as a global orientation reflecting an individual's feeling of confidence in both the predictability of their internal and external environment and their ability to cope with stressful and challenging situations in life - shows a negative association with symptoms of post-traumatic stress. However, single studies varying in study characteristics provide heterogeneous effect size estimations. Objective: The purpose of the current study is to investigate the relationship between SOC and post-traumatic stress disorder (PTSD) symptom severity for the first time on a meta-analytical level. Method: The random-effects meta-analysis is based on zero-order correlations (r) and consists of 47 independent samples out of 45 studies (N = 10,883). Results: After correcting for sampling error, the mean correlation between SOC and PTSD symptoms was M(r) = -.41 (excluding four outliers: -.39). However, this effect could not be generalized to all types of PTSD samples owing to substantial remaining heterogeneity. Subsequent moderator analyses investigating the influence of different SOC and PTSD measures, trauma type and duration, mean age and gender imbalances per sample did not reveal significant moderating effects. Conclusions: The meta-analysis reveals a substantial correlation between SOC and PTSD symptom severity: higher SOC levels are associated with lower symptom severity. Thus, future research should progress to the question of whether the relationship between SOC and post-traumatic stress is causal, and by which factors it is moderated. Abbreviations: CD, Cook's distance; DSM, Diagnostic and Statistical Manual of Mental Disorders; (G)RR, general (and specific) resistance resources; IES(-R), Impact of Event Scale (Revised); PDS, Posttraumatic Stress Diagnostic Scale; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PTSD, post-traumatic stress disorder; SDR, standard deleted residual; SOC, sense of coherence; SOC-R, Sense of Coherence Scale - Revised.
Collapse
Affiliation(s)
- S K Schäfer
- Division of Clinical Psychology and Psychotherapy, Department of Psychology, Saarland University, Saarbrücken, Germany
| | - N Becker
- Individual Differences & Psychodiagnostics, Department of Psychology, Saarland University, Saarbrücken, Germany
| | - L King
- The Oxford Institute of Clinical Psychology Training, Isis Education Centre, Warneford Hospital, Oxford, UK
| | - A Horsch
- Department Woman-Mother-Child, Lausanne University Hospital, Lausanne, Switzerland.,Institute of Higher Education in Healthcare Research, University of Lausanne, Lausanne, Switzerland
| | - T Michael
- Division of Clinical Psychology and Psychotherapy, Department of Psychology, Saarland University, Saarbrücken, Germany
| |
Collapse
|
26
|
Rotordam MG, Fermo E, Becker N, Barcellini W, Brüggemann A, Fertig N, Egée S, Rapedius M, Bianchi P, Kaestner L. A novel gain-of-function mutation of Piezo1 is functionally affirmed in red blood cells by high-throughput patch clamp. Haematologica 2018; 104:e179-e183. [PMID: 30237269 DOI: 10.3324/haematol.2018.201160] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Maria G Rotordam
- Saarland University, Theoretical Medicine and Biosciences, Homburg/Saar, Germany.,Nanion Technologies GmbH, Munich, Germany
| | - Elisa Fermo
- UOC Ematologia, UOS Fisiopatologia delle Anemie, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | | | - Wilma Barcellini
- UOC Ematologia, UOS Fisiopatologia delle Anemie, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | | | | | - Stéphane Egée
- Sorbonne Université, CNRS, UMR 8227, Integrative Biology of Marine Models, Station Biologique de Roscoff, Roscoff Cedex, France.,Laboratoire d'Excellence GR-Ex, Paris, France
| | | | - Paola Bianchi
- UOC Ematologia, UOS Fisiopatologia delle Anemie, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - Lars Kaestner
- Saarland University, Theoretical Medicine and Biosciences, Homburg/Saar, Germany .,Saarland University, Experimental Physics, Saarbrücken, Germany
| |
Collapse
|
27
|
Bot C, Becker N, Goversen B, Stoelzle-Feix S, Obergrussberger A, van Veen TA, Fertig N, de Boer TP. Introducing Simulated IK1 into Human iPSC-Cardiomyocytes using Dynamic Clamp on an Automated Patch Clamp Platform. Biophys J 2018. [DOI: 10.1016/j.bpj.2017.11.1747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
28
|
Goversen B, Becker N, Stoelzle-Feix S, Obergrussberger A, Vos MA, van Veen TAB, Fertig N, de Boer TP. A Hybrid Model for Safety Pharmacology on an Automated Patch Clamp Platform: Using Dynamic Clamp to Join iPSC-Derived Cardiomyocytes and Simulations of I k1 Ion Channels in Real-Time. Front Physiol 2018; 8:1094. [PMID: 29403387 PMCID: PMC5782795 DOI: 10.3389/fphys.2017.01094] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Accepted: 12/12/2017] [Indexed: 11/20/2022] Open
Abstract
An important aspect of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) proposal is the use of human stem cell-derived cardiomyocytes and the confirmation of their predictive power in drug safety assays. The benefits of this cell source are clear; drugs can be tested in vitro on human cardiomyocytes, with patient-specific genotypes if needed, and differentiation efficiencies are generally excellent, resulting in a virtually limitless supply of cardiomyocytes. There are, however, several challenges that will have to be surmounted before successful establishment of hSC-CMs as an all-round predictive model for drug safety assays. An important factor is the relative electrophysiological immaturity of hSC-CMs, which limits arrhythmic responses to unsafe drugs that are pro-arrhythmic in humans. Potentially, immaturity may be improved functionally by creation of hybrid models, in which the dynamic clamp technique joins simulations of lacking cardiac ion channels (e.g., IK1) with hSC-CMs in real-time during patch clamp experiments. This approach has been used successfully in manual patch clamp experiments, but throughput is low. In this study, we combined dynamic clamp with automated patch clamp of iPSC-CMs in current clamp mode, and demonstrate that IK1 conductance can be added to iPSC-CMs on an automated patch clamp platform, resulting in an improved electrophysiological maturity.
Collapse
Affiliation(s)
- Birgit Goversen
- Division of Heart & Lungs, Department of Medical Physiology, University Medical Center Utrecht, Utrecht, Netherlands
| | | | | | | | - Marc A Vos
- Division of Heart & Lungs, Department of Medical Physiology, University Medical Center Utrecht, Utrecht, Netherlands
| | - Toon A B van Veen
- Division of Heart & Lungs, Department of Medical Physiology, University Medical Center Utrecht, Utrecht, Netherlands
| | | | - Teun P de Boer
- Division of Heart & Lungs, Department of Medical Physiology, University Medical Center Utrecht, Utrecht, Netherlands
| |
Collapse
|
29
|
Obergrussberger A, Goetze TA, Brinkwirth N, Becker N, Friis S, Rapedius M, Haarmann C, Rinke-Weiß I, Stölzle-Feix S, Brüggemann A, George M, Fertig N. An update on the advancing high-throughput screening techniques for patch clamp-based ion channel screens: implications for drug discovery. Expert Opin Drug Discov 2018; 13:269-277. [DOI: 10.1080/17460441.2018.1428555] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
30
|
Abstract
Zusammenfassung
Gegenstand und Ziel: Gewinn epidemiologischer Daten zur Fütterung von Hunden und Katzen in Deutschland.
Material und Methoden: 865 Hundeund 243 Katzenbesitzer wurden anhand standardisierter Fragebögen zu ihrem Tier (Alter, Geschlecht, Gewicht, Ernährungszustand, Gesundheit), dessen Fütterung inklusive Belohnungen und Zusätzen, den Gründen für eine Futterumstellung und zur eigenen Person (Alter, Geschlecht, Schulbildung, Beruf) befragt. Die Befragungen fanden in Tierarztpraxen, Hundeschulen, Tierheimen, Parkanlagen und via Internet statt. Zudem wurde der Body Condition Score (BCS) der Tiere durch ihre Besitzer sowie die Interviewerin beurteilt.
Ergebnisse: Das Durchschnittsalter der Hunde lag bei 4,8 Jahren, das der Katzen bei 6,8 Jahren. Das Gewicht reichte beim Hund von 2,2 bis 95 kg, bei der Katze von 2 bis 11 kg. Rund 52% der Hunde und Katzen waren übergewichtig (BCS 6–9). Zwischen der Beurteilung der Besitzer bzw. der Interviewerin gab es Differenzen. Viele Besitzer unterschätzten den BCS und erkannten vor allem beginnendes Übergewicht (BCS 6–7) nicht. 58% der Hundeund 90% der Katzenbesitzer verwendeten ausschließlich handelsübliche Fertigfutter, 35% bzw. knapp 10% kombinierten diese mit zusätzlichen Futtermitteln. Knapp 8% der Hundeund < 1% der Katzenbesitzer verfütterten selbst zubereitete Rationen. Ältere (> 7 Jahre) und kranke Hunde erhielten häufiger selbst hergestellte Rationen. Ältere Besitzer (≥ 46 Jahre) tendierten vermehrt dazu, das Futter selbst zuzubereiten, während die Schulbildung und die Berufstätigkeit keinen Einfluss auf die Fütterung hatten. Ein Zusammenhang zwischen Art der Fütterung und BCS bestand nicht. Besitzer mit geringerer Schulbildung sowie Hausfrauen und Rentner hatten häufiger übergewichtige Tiere. Futterbelohnungen erhielten 95% der Hunde und 65% der Katzen. Ältere und berufstätige Besitzer gaben prozentual seltener Belohnungen.
Schlussfolgerungen: Übergewicht ist das größte ernährungsbedingte Problem. Im Vergleich zu früheren Studien hat sich die Zahl übergewichtiger Tiere erhöht.
Klinische Relevanz: Tierbesitzer sollten frühzeitig auf Übergewicht hingewiesen werden, da sie den Beginn der Adipositas häufig nicht wahrnehmen. Die meisten Tierbesitzer verabreichen Belohnungen, was bei Diäten berücksichtigt werden muss.
Collapse
|
31
|
Bot C, Stölzle-Feix S, Becker N, Thomas U, Juhasz K, Doerr L, Beckler M, Haarmann C, Obergrussberger A, Rapedius M, Götze T, Vogel M, George M, Brüggemann A, Haedo R, Fertig N. An “All Inclusive “Package for Cardiac Safety: The Six Big on One Automated Patch Clamp Chip. J Pharmacol Toxicol Methods 2017. [DOI: 10.1016/j.vascn.2017.09.090] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
32
|
Bot C, Stölzle-Feix S, Becker N, Thomas U, Juhasz K, Doerr L, Beckler M, George M, Brüggemann A, Haedo R, Fertig N. Impedance and Extracellular Field Potential for Cardiac Safety Assays: A Combined Approach for Non-Invasive Screening of iPS Cells. J Pharmacol Toxicol Methods 2017. [DOI: 10.1016/j.vascn.2017.09.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
33
|
Zeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J, Ho AD, Zeier M, Dreger P, Luft T. Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant 2017. [PMID: 28650448 DOI: 10.1038/bmt.2017.119] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
There is increasing evidence that endothelial dysfunction is involved in refractoriness of acute GvHD (aGvHD). Here we investigated the hypothesis that another endothelial complication, transplant-associated thrombotic microangiopathy (TMA), contributes to the pathogenesis of aGvHD refractoriness. TMA was retrospectively assessed in 771 patients after allogeneic stem cell transplantation (alloSCT). Incidences of TMA and refractory aGvHD were correlated with biomarkers of endothelial damage obtained before alloSCT for patients receiving or not receiving statin-based endothelial prophylaxis (SEP). Diagnostic criteria for TMA and refractory aGvHD were met by 41 (5.3%) and 76 (10%) patients, respectively. TMA was overrepresented in patients with refractory aGvHD (45.0 vs 2.3% in all other patients, P<0.001). TMA independently increased mortality. Elevated pretransplant suppressor of tumorigenicity-2 and nitrates along with high-risk variants of the thrombomodulin gene were associated with increased risk of TMA. In contrast, SEP abolished the unfavorable outcome predicted by pretransplant biomarkers on TMA risk. Patients on SEP had a significantly lower risk of TMA (P=0.001) and refractory aGvHD (P=0.055) in a multivariate multistate model. Our data provide evidence that TMA contributes to the pathogenesis of aGvHD refractoriness. Patients with an increased TMA risk can be identified pretransplant and may benefit from pharmacological endothelium protection.
Collapse
Affiliation(s)
- M Zeisbrich
- Department of Nephrology, University of Heidelberg, Heidelberg, Germany
| | - N Becker
- Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany
| | - A Benner
- Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany
| | - A Radujkovic
- Department of Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany
| | - K Schmitt
- Department of Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany
| | - J Beimler
- Department of Nephrology, University of Heidelberg, Heidelberg, Germany
| | - A D Ho
- Department of Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany
| | - M Zeier
- Department of Nephrology, University of Heidelberg, Heidelberg, Germany
| | - P Dreger
- Department of Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany
| | - T Luft
- Department of Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany
| |
Collapse
|
34
|
Oehme R, Becker N, Jöst A. Aktuelle Situation zum Monitoring und der Bekämpfung von Aedes albopictus in Baden-Württemberg. Gesundheitswesen 2017. [DOI: 10.1055/s-0037-1602111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- R Oehme
- Landesgesundheitsamt Baden-Württemberg, Stuttgart
| | - N Becker
- Kommunale Aktionsgemeinschaft zur Bekämpfung der Stechmückenplage e.V. (KABS)/Institut für Dipterologie (IfD)/Universität Heidelberg, Speyer
| | - A Jöst
- Kommunale Aktionsgemeinschaft zur Bekämpfung der Stechmückenplage e.V. (KABS)/Institut für Dipterologie (IfD)/Universität Heidelberg, Speyer
| |
Collapse
|
35
|
Kanis J, Link V, Dippon C, Becker N, Kübler A. Schlaf, Kindlein, schlaf? Somnologie 2016. [DOI: 10.1007/s11818-016-0092-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
36
|
Bissonnette J, Bezjak A, Becker N, Vines D, Sun A. Serial 4-Dimensional (4D) Computed Tomography/4D Positron Emission Tomography Imaging to Predict and Monitor Response for Locally Advanced Non-Small Cell Lung Cancer Radiation Therapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
37
|
Millard DC, Strock CJ, Carlson CB, Aoyama N, Juhasz K, Goetze TA, Stoelzle-Feix S, Becker N, Fertig N, January CT, Anson BD, Ross JD. Identification of Drug-Drug Interactions In Vitro: A Case Study Evaluating the Effects of Sofosbuvir and Amiodarone on hiPSC-Derived Cardiomyocytes. Toxicol Sci 2016; 154:174-182. [PMID: 27503387 DOI: 10.1093/toxsci/kfw153] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Drug-drug interactions pose a difficult drug safety problem, given the increasing number of individuals taking multiple medications and the relative complexity of assessing the potential for interactions. For example, sofosbuvir-based drug treatments have significantly advanced care for hepatitis C virus-infected patients, yet recent reports suggest interactions with amiodarone may cause severe symptomatic bradycardia and thus limit an otherwise extremely effective treatment. Here, we evaluated the ability of human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) to recapitulate the interaction between sofosbuvir and amiodarone in vitro, and more generally assessed the feasibility of hiPSC-CMs as a model system for drug-drug interactions. Sofosbuvir alone had negligible effects on cardiomyocyte electrophysiology, whereas the sofosbuvir-amiodarone combination produced dose-dependent effects beyond that of amiodarone alone. By comparison, GS-331007, the primary circulating metabolite of sofosbuvir, had no effect alone or in combination with amiodarone. Further mechanistic studies revealed that the sofosbuvir-amiodarone combination disrupted intracellular calcium (Ca2+) handling and cellular electrophysiology at pharmacologically relevant concentrations, and mechanical activity at supra-pharmacological (30x Cmax) concentrations. These effects were independent of the common mechanisms of direct ion channel block and P-glycoprotein activity. These results support hiPSC-CMs as a comprehensive, yet scalable model system for the identification and evaluation of cardioactive pharmacodynamic drug-drug interactions.
Collapse
Affiliation(s)
| | | | - Coby B Carlson
- Cellular Dynamics International, a Fujifilm Company, Madison, Wisconsin
| | - Natsuyo Aoyama
- Cellular Dynamics International, a Fujifilm Company, Madison, Wisconsin
| | - Krisztina Juhasz
- Nanion Technologies GmbH, Munich, Germany
- Technische Universitat Munchen, Munich, Germany
| | | | | | | | | | - Craig T January
- School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin
| | - Blake D Anson
- Cellular Dynamics International, a Fujifilm Company, Madison, Wisconsin
| | | |
Collapse
|
38
|
Lühken R, Czajka C, Steinke S, Jöst H, Schmidt-Chanasit J, Pfitzner W, Becker N, Kiel E, Krüger A, Tannich E. Distribution of individual members of the mosquito Anopheles maculipennis complex in Germany identified by newly developed real-time PCR assays. Med Vet Entomol 2016; 30:144-154. [PMID: 26787387 DOI: 10.1111/mve.12161] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/26/2015] [Revised: 11/02/2015] [Accepted: 11/23/2015] [Indexed: 06/05/2023]
Abstract
Owing to their role as vectors of malaria parasites, species of the Anopheles maculipennis complex (Diptera: Culicidae) Meigen were intensively studied in the past, but with the disappearance of malaria in Germany in the middle of the last century, the interest in this field of research declined. A comprehensive ecological analysis of the current species distribution for Germany is lacking. Between 2010 and 2013, a total of 1445 mosquitoes of the An. maculipennis complex were collected at 72 different sites in Germany. The samples comprise 722 single individuals as well as 723 individuals in 90 pools of up to 25 mosquitoes. All samples were analysed with newly developed species-specific qPCR assays for the identification of the four German species using nucleotide differences within the internal transcribed spacer 2 (ITS2) ribosomal DNA. All gathered data were used for species distribution modelling. The overall prevalence of An. messeae s.l. was highest with 98.89% of all pools; An. daciae with 6.93% of all individuals and An. messeae s.s. with 69.53%. The prevalence of the other two species was relatively low: An. maculipennis s.s. with 13.30% of all individuals (6.67% of all pools) and An. atroparvus with 1.80% of all individuals (1.11% of all pools).
Collapse
Affiliation(s)
- R Lühken
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- Research Group Aquatic Ecology and Nature Conservation, Carl von Ossietzky University Oldenburg, Germany
| | - C Czajka
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - S Steinke
- Research Group Aquatic Ecology and Nature Conservation, Carl von Ossietzky University Oldenburg, Germany
| | - H Jöst
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- German Centre for Infection Research, Hamburg, Germany
| | - J Schmidt-Chanasit
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- German Centre for Infection Research, Hamburg, Germany
| | - W Pfitzner
- German Mosquito Control Association (KABS e.V.), Institute for Dipterology, Oldenburg, Waldsee, Germany
| | - N Becker
- German Mosquito Control Association (KABS e.V.), Institute for Dipterology, Oldenburg, Waldsee, Germany
- University of Heidelberg, Heidelberg, Germany
| | - E Kiel
- Research Group Aquatic Ecology and Nature Conservation, Carl von Ossietzky University Oldenburg, Germany
| | - A Krüger
- Bundeswehr Hospital Hamburg, Hamburg, Germany
| | - E Tannich
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- German Centre for Infection Research, Hamburg, Germany
| |
Collapse
|
39
|
Bot C, Stoelzle-Feix S, Becker N, Juhasz K, Thomas U, Doerr L, Haedo R, Beckler M, Oestreich J, George M, Brüggemann A, Fertig N. Impedance and Combined Extracellular Field Potential Recordings of CiPA Reference Compounds on IPS Cardiomyocytes. Biophys J 2016. [DOI: 10.1016/j.bpj.2015.11.1474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
40
|
Obergrussberger A, Bru ggemann A, Goetze TA, Rapedius M, Haarmann C, Rinke I, Becker N, Oka T, Ohtsuki A, Stengel T, Vogel M, Steindl J, Mueller M, Stiehler J, George M, Fertig N. Automated Patch Clamp Meets High-Throughput Screening: 384 Cells Recorded in Parallel on a Planar Patch Clamp Module. ACTA ACUST UNITED AC 2015; 21:779-793. [DOI: 10.1177/2211068215623209] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2015] [Indexed: 11/15/2022]
|
41
|
Abstract
Ion channels are integral membrane proteins that regulate the flux of ions across the cell membrane. They are involved in nearly all physiological processes, and malfunction of ion channels has been linked to many diseases. Until recently, high-throughput screening of ion channels was limited to indirect, e.g. fluorescence-based, readout technologies. In the past years, direct label-free biophysical readout technologies by means of electrophysiology have been developed. Planar patch-clamp electrophysiology provides a direct functional label-free readout of ion channel function in medium to high throughput. Further electrophysiology features, including temperature control and higher-throughput instruments, are continually being developed. Electrophysiological screening in a 384-well format has recently become possible. Advances in chip and microfluidic design, as well as in cell preparation and handling, have allowed challenging cell types to be studied by automated patch clamp. Assays measuring action potentials in stem cell-derived cardiomyocytes, relevant for cardiac safety screening, and neuronal cells, as well as a large number of different ion channels, including fast ligand-gated ion channels, have successfully been established by automated patch clamp. Impedance and multi-electrode array measurements are particularly suitable for studying cardiomyocytes and neuronal cells within their physiological network, and to address more complex physiological questions. This article discusses recent advances in electrophysiological technologies available for screening ion channel function and regulation.
Collapse
Affiliation(s)
| | | | | | | | | | - Clemens Möller
- b Albstadt-Sigmaringen University; Life Sciences Faculty ; Sigmaringen , Germany
| |
Collapse
|
42
|
Schimmöller L, Quentin M, Blondin D, Rabenalt R, Becker N, Gabbert H, Albers P, Antoch G, Arsov C. Risikoreduktion eines Gleason-Upgrades bei der radikalen Prostatektomie durch gezielte MRT-Biopsieverfahren. ROFO-FORTSCHR RONTG 2015. [DOI: 10.1055/s-0035-1551438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
43
|
Becker N, Krüger A, Kuhn C, Plenge-Bönig A, Thomas SM, Schmidt-Chanasit J, Tannich E. [Mosquitoes as vectors for exotic pathogens in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2015; 57:531-40. [PMID: 24781910 DOI: 10.1007/s00103-013-1918-8] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
As a result of intensified globalization of international trade and of substantial travel activities, mosquito-borne exotic pathogens are becoming an increasing threat for Europe. In Germany some 50 different mosquito species are known, several of which have vector competence for pathogens. During the last few years a number of zoonotic arboviruses that are pathogenic for humans have been isolated from mosquitoes in Germany including Usutu, Sindbis and Batai viruses. In addition, filarial worms, such as Dirofilaria repens have been repeatedly detected in mosquitoes from the federal state of Brandenburg. Other pathogens, in particular West Nile virus, are expected to emerge sooner or later in Germany as the virus is already circulating in neighboring countries, e.g. France, Austria and the Czech Republic. In upcoming years the risk for arbovirus transmission might increase in Germany due to increased occurrence of new so-called "invasive" mosquito species, such as the Asian bush mosquito Ochlerotatus japonicus or the Asian tiger mosquito Aedes albopictus. These invasive species are characterized by high vector competence for a broad range of pathogens and a preference for human blood meals. For risk assessment, a number of mosquito and pathogen surveillance projects have been initiated in Germany during the last few years; however, mosquito control strategies and plans of action have to be developed and put into place to allow early and efficient action against possible vector-borne epidemics.
Collapse
|
44
|
Costas L, Infante-Rivard C, Zock JP, Van Tongeren M, Boffetta P, Cusson A, Robles C, Casabonne D, Benavente Y, Becker N, Brennan P, Foretova L, Maynadié M, Staines A, Nieters A, Cocco P, de Sanjosé S. Occupational exposure to endocrine disruptors and lymphoma risk in a multi-centric European study. Br J Cancer 2015; 112:1251-6. [PMID: 25742473 PMCID: PMC4385964 DOI: 10.1038/bjc.2015.83] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Revised: 01/02/2015] [Accepted: 01/27/2015] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Incidence rates of lymphoma are usually higher in men than in women, and oestrogens may protect against lymphoma. METHODS We evaluated occupational exposure to endocrine disrupting chemicals (EDCs) among 2457 controls and 2178 incident lymphoma cases and subtypes from the European Epilymph study. RESULTS Over 30 years of exposure to EDCs compared to no exposure was associated with a 24% increased risk of mature B-cell neoplasms (P-trend=0.02). Associations were observed among men, but not women. CONCLUSIONS Prolonged occupational exposure to endocrine disruptors seems to be moderately associated with some lymphoma subtypes.
Collapse
Affiliation(s)
- L Costas
- Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 Barcelona, Spain
- Department of Medicine, University of Barcelona, 08036 Barcelona, Spain
- CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
| | - C Infante-Rivard
- Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine, McGill University, Montréal, QC, Canada H3A 1A2
| | - J-P Zock
- CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Netherlands Institute for Health Services Research (NIVEL), 3500 Utrecht, The Netherlands
- Centre for Research in Environmental Epidemiology (CREAL), 08003 Barcelona, Spain
- Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
| | - M Van Tongeren
- Centre for Human Exposure Science (CHES), Institute of Occupational Medicine, EH14 4AP Edinburgh, UK
| | - P Boffetta
- Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, 10029 NY, USA
| | - A Cusson
- Centre de Recherche, CHU Sainte-Justine, Montréal, QC, Canada H3T 1C4
| | - C Robles
- Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 Barcelona, Spain
| | - D Casabonne
- Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 Barcelona, Spain
- CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
| | - Y Benavente
- Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 Barcelona, Spain
- CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
| | - N Becker
- Division of Cancer Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
| | - P Brennan
- IARC, International Agency for Research on Cancer, 69372 Lyon, France
| | - L Foretova
- Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute and MF MU, 65653 Brno, Czech Republic
| | - M Maynadié
- Biological Hematology Unit, CRB Ferdinand Cabanne, Universitary Hospital of Dijon and EA4184, University of Burgundy, EA 4184 Dijon, France
| | - A Staines
- Public Health University College, Dublin, Ireland
| | - A Nieters
- Centre of Chronic Immunodeficiency, Molecular Epidemiology, University Medical Center Freiburg, 79106 Freiburg, Germany
| | - P Cocco
- Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, 09124 Cagliari, Italy
| | - S de Sanjosé
- Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 Barcelona, Spain
- Department of Medicine, University of Barcelona, 08036 Barcelona, Spain
- CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
| |
Collapse
|
45
|
Kirk MD, Moffatt CRM, Hall GV, Becker N, Booy R, Heron L, MacIntyre R, Dwyer DE, Lindley R. The Burden of Infectious Gastroenteritis in Elderly Residents and Staff of Long-Term Care Facilities, Australia. Infect Control Hosp Epidemiol 2015; 31:860-3. [DOI: 10.1086/654000] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
We estimated the incidence of gastroenteritis in 16 Australian long-term care facilities. During 12 months' surveillance, 245 (96%) of 254 episodes of gastroenteritis among long-term care residents were associated with 17 outbreaks in 11 facilities. Incidence in long-term care residents was 0.64 episodes per 1,000 bed-days (95% confidence interval, 0.29-1.42).
Collapse
|
46
|
Foresti GR, Becker N, Silva AS, Almeida WRR, Malesuik MD, Hass SE, Silva FEB. An Alternative Method for the Dissolution of Enrofloxacin Tablets. DISSOLUT TECHNOL 2015. [DOI: 10.14227/dt220115p23] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
47
|
Gross G, Becker N, Brockmeyer N, Esser S, Freitag U, Gebhardt M, Gissmann L, Hillemanns P, Grundhewer H, Ikenberg H, Jessen H, Kaufmann A, Klug S, Klussmann J, Nast A, Pathirana D, Petry K, Pfister H, Röllinghof U, Schneede P, Schneider A, Selka E, Singer S, Smola S, Sporbeck B, von Knebel Doeberitz M, Wutzler P. Impfprävention HPV-assoziierter Neoplasien. Laryngorhinootologie 2014; 93:848-56. [DOI: 10.1055/s-0034-1382013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- G. Gross
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin, Universität Rostock, Rostock
| | - N. Becker
- Deutsches Krebsforschungszentrum (DKFZ), Epidemiologie von Krebserkrankungen (C020), Heidelberg
| | - N. Brockmeyer
- Klinik für Dermatologie und Allergologie der Ruhr-Universität, Bochum
| | - S. Esser
- Klinik für Dermatologie und Venerologie, Universitätsklinikum Essen, Essen
| | | | | | - L. Gissmann
- Deutsches Krebsforschungszentrum (DKFZ), FS Infektion und Krebs, Heidelberg
| | - P. Hillemanns
- Medizinische Hochschule Hannover (MHH), Frauenklinik, Abt. I für Frauenheilkunde und Geburtshilfe, Hannover
| | - H. Grundhewer
- Ausschuss Prävention des Berufsverbandes der Kinder- und Jugendärzte (BVKJ), Berlin
| | - H. Ikenberg
- MVZ für Zytologie und Molekularbiologie (CytoMol), Frankfurt/M
| | | | - A. Kaufmann
- Gynäkologische Tumorimmunologie, Gynäkologie mit Hochschulambulanz, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin
| | - S. Klug
- Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden
| | - J. Klussmann
- Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Klinikum der Universität Gießen, Gießen
| | - A. Nast
- Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Allergologie und Venerologie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin
| | - D. Pathirana
- Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Allergologie und Venerologie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin
| | - K. Petry
- Klinikum Wolfsburg, Abteilung Gynäkologische Onkologie, Wolfsburg
| | - H. Pfister
- Institut für Virologie der Universität zu Köln
| | | | - P. Schneede
- Klinikum Memmingen, Klinik für Urologie, Memmingen
| | - A. Schneider
- Klinik und Poliklinik für Gynäkologie, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin
| | - E. Selka
- VulvaKarzinom-SHG e. V., Wilhelmshaven
| | - S. Singer
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Institut für Medizinische Biometrie, Epidemiologie und Informatik, Abt. Epidemiologie und Versorgungsforschung, Mainz
| | - S. Smola
- Institut für Virologie, Institut für Infektionsmedizin, Universität des Saarlandes, Homburg/Saar
| | - B. Sporbeck
- Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Allergologie und Venerologie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin
| | - M. von Knebel Doeberitz
- Abteilung für Molekulare Pathologie, Pathologisches Institut des Universitätsklinikum Heidelberg, Heidelberg
| | - P. Wutzler
- Universitätsklinikum Jena (Friedrich-Schiller-Universität), Institut für Virologie und Antivirale Therapie, Beutenberg Campus, Jena
| |
Collapse
|
48
|
Yap M, Sun A, Higgins J, Marshall A, Becker N, Le L, Clarke K, Vines D, Bezjak A, Bissonnette J. Adaptive Dose-Escalation Using Serial 4D-PET/CT Scans During Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
49
|
Haug U, Rösch T, Hoffmeister M, Katalinic A, Brenner H, Becker N. [Implementing an Organised Colorectal Cancer Screening Programme in Germany: Opportunities and Challenges]. Gesundheitswesen 2014; 77:869-74. [PMID: 25025294 DOI: 10.1055/s-0034-1377027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
BACKGROUND Each year in Germany, about 65,000 people are diagnosed with colorectal cancer (CRC) and more than 25,000 people die of the disease. The majority of these cases could be avoided by a more effective screening programme. Recently, a law came into force that offers a great opportunity in this regard. It calls for introducing an organised CRC screening programme in Germany, which includes an invitation system as well as further measures for quality assurance and programme evaluation. To realise this opportunity, challenges of implementation need to be considered. The aim of this review article is to elaborate the challenges of an organised CRC screening in Germany in order to derive the need for action regarding successful implementation. METHODS This review article is based on a selective literature search, including current guidelines and recommendations. RESULTS AND CONCLUSION In the context of CRC screening, but also by colonoscopies performed for other indications (e.g., due to symptoms), precancerous lesions (adenomas) are detected and removed in a relevant proportion of the target population, which requires a surveillance examination after 3 or 5 years according to current recommendations. Therefore, an efficient invitation system for CRC screening should be designed to allow for a flexible interval depending on previous findings, which differs from mammography screening with its fixed interval. A prerequisite would be the standardised documentation of all colonoscopies irrespective of the indication, given that a substantial proportion of colonoscopies in Germany are performed outside of the screening program. Still, the work load regarding documentation could be less than for mammography screening. Another challenge in terms of organisation results from the parallel offer of 2 different screening tools (colonoscopy and faecal occult blood test). To realise the potential of an organised CRC screening, it seems important to devote sufficient time and resources for developing an efficient and feasible concept, while there might be interim options to avoid further delay regarding the initial invitation of the target population. Given that expertise from, amongst others, gastroenterology, epidemiology, clinical chemistry and health communication is required, an interdisciplinary approach appears essential.
Collapse
Affiliation(s)
- U Haug
- Epidemiologisches Krebsregister Baden-Württemberg, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
| | - T Rösch
- Klinik und Poliklinik für Interdisziplinäre Endoskopie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - M Hoffmeister
- Abteilung für Klinische Epidemiologie und Alternsforschung, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
| | - A Katalinic
- Institut für Sozialmedizin und Epidemiologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck
| | - H Brenner
- Abteilung für Klinische Epidemiologie und Alternsforschung, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
| | - N Becker
- Epidemiologisches Krebsregister Baden-Württemberg, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
| |
Collapse
|
50
|
Obergrussberger A, Haarmann C, Rinke I, Becker N, Guinot D, Brueggemann A, Stoelzle‐Feix S, George M, Fertig N. Automated Patch Clamp Analysis of nAChα7 and Na
V
1.7 Channels. ACTA ACUST UNITED AC 2014; 65:11.13.1-48. [DOI: 10.1002/0471141755.ph1113s65] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|